{
  "schema_version": 1,
  "kind": "drug_profile",
  "generic": "triamcinolone",
  "review_status": "reviewed",
  "origin": "openfda",
  "sections": {
    "adult": [
      {
        "text": "The initial dose of triamcinolone acetonide injectable suspension may vary from 2.5 mg to 100 mg per day depending on the specific disease entity being treated (see Dosage section below).",
        "source": "US FDA label for triamcinolone (Triamcinolone Acetonide), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/triamcinolone.json",
        "verbatim": true
      },
      {
        "text": "Dosage SYSTEMIC The suggested initial dose is 60 mg, injected deeply into the gluteal muscle .",
        "source": "US FDA label for triamcinolone (Triamcinolone Acetonide), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/triamcinolone.json",
        "verbatim": true
      },
      {
        "text": "However, some patients may be well controlled on doses as low as 20 mg or less.",
        "source": "US FDA label for triamcinolone (Triamcinolone Acetonide), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/triamcinolone.json",
        "verbatim": true
      }
    ],
    "child": [
      {
        "text": "General NOTE: CONTAINS BENZYL ALCOHOL (see PRECAUTIONS). The initial dose of triamcinolone acetonide injectable suspension may vary from 2.5 mg to 100 mg per day depending on the specific disease entity being treated (see Dosage section below). However, in certain overwhelming, acute, life-threatening situations, administration in dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages.",
        "source": "US FDA label for triamcinolone (Triamcinolone Acetonide), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/triamcinolone.json",
        "verbatim": true
      },
      {
        "text": "The range of initial doses is 0.11 mg/kg/day to 1.6 mg/kg/day in 3 or 4 divided doses (3.2 mg/m 2 bsa/day to 48 mg/m 2 bsa/day).",
        "source": "US FDA label for triamcinolone (Triamcinolone Acetonide), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/triamcinolone.json",
        "verbatim": true
      }
    ],
    "renal": [
      {
        "text": "No kidney-impairment dose in this label. Not a statement that none is needed.",
        "source": "Read and found silent: the US FDA label for triamcinolone (Triamcinolone Acetonide), retrieved 2026-08-29",
        "cached_file": "labels/triamcinolone.json",
        "verbatim": false
      }
    ],
    "hepatic": [
      {
        "text": "No liver-impairment dose in this label. Not a statement that none is needed.",
        "source": "Read and found silent: the US FDA label for triamcinolone (Triamcinolone Acetonide), retrieved 2026-08-29",
        "cached_file": "labels/triamcinolone.json",
        "verbatim": false
      }
    ],
    "pregnancy": [
      {
        "text": "Neuro-Psychiatric Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that they affect the ultimate outcome or natural history of the disease.",
        "source": "US FDA label for triamcinolone (Triamcinolone Acetonide), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/triamcinolone.json",
        "verbatim": true
      },
      {
        "text": "The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect.",
        "source": "US FDA label for triamcinolone (Triamcinolone Acetonide), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/triamcinolone.json",
        "verbatim": true
      },
      {
        "text": "An acute myopathy has been observed with the use of high doses of corticosteroids, most often occurring in patients with disorders of neuromuscular transmission (e.g., myasthenia gravis), or in patients receiving concomitant therapy with neuromuscular blocking drugs ( e.g., pancuronium).",
        "source": "US FDA label for triamcinolone (Triamcinolone Acetonide), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/triamcinolone.json",
        "verbatim": true
      }
    ],
    "lactation": [
      {
        "text": "Information for Patients Patients should be warned not to discontinue the use of corticosteroids abruptly or without medical supervision, to advise any medical attendants that they are taking corticosteroids, and to seek medical advice at once should they develop fever or other signs of infection.",
        "source": "US FDA label for triamcinolone (Triamcinolone Acetonide), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/triamcinolone.json",
        "verbatim": true
      },
      {
        "text": "Persons who are on corticosteroids should be warned to avoid exposure to chicken pox or measles.",
        "source": "US FDA label for triamcinolone (Triamcinolone Acetonide), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/triamcinolone.json",
        "verbatim": true
      },
      {
        "text": "Patients should also be advised that if they are exposed, medical advice should be sought without delay.",
        "source": "US FDA label for triamcinolone (Triamcinolone Acetonide), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/triamcinolone.json",
        "verbatim": true
      }
    ]
  }
}